Skip to content
Novo Nordisk & Oslo University

Novo Nordisk & Oslo University

Semaglutide is a peptide that acts as a GLP-1 agonist, similar to the other therapies in this list. It is being studied for its potential neuroprotective properties, aiming to reduce neuroinflammation and oxidative stress in Parkinson’s disease and thereby slow disease progression.

Cart 0

Your cart is currently empty.

Start Shopping